Strategic Options
Elevation Oncology Discontinues Lead Drug and Cuts Workforce
EO-3021, Claudin 18.2 ADC, Phase 1 trial, gastric cancer, layoffs, strategic options
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development
Tome Biosciences Halts Operations Amid Financial Strains, CEO Focuses on Strategic Deals
Tome Biosciences, gene editing, layoffs, financial struggles, strategic options, Rahul Kakkar
TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options
TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales